Developing Wound Cures...
not Wound Care
Dermatherix is a pioneering biotech company dedicated to advancing wound therapies through innovative research.
Our focus is on exploring the therapeutic potential of 3K3A-APC, a novel variant of Activated Protein C (APC), in treating wounds.
Our work represents a significant step forward in the quest to develop solutions that not only accelerate healing but also improve outcomes for patients with challenging wound conditions.
Millions of people globally suffer from chronic non-healing wounds
A chronic wound is a wound that fails to progress through the normal phases of healing in an orderly and timely manner. The most common types of chronic wounds include diabetic foot ulcers, venous leg ulcers, pressure ulcers (bedsores), and arterial ulcers. ​
Non-healing wounds are at a high risk of becoming infected, which can lead to serious complications such as sepsis, osteomyelitis (bone infection), and gangrene.
​
Particularly in diabetic foot ulcers, there is a significant risk of limb amputation if the wound does not heal. This not only impacts mobility and quality of life but also increases mortality risk.
Chronic wounds place a substantial financial and resource burden on healthcare systems. The cost of treating chronic wounds in the United States of America is estimated to be around $20 billion annually and expected to grow to $31 billion by 2030. This includes expenses related to prolonged treatment, hospitalizations, surgeries, and long-term care.
​
10.5 million US Medicare users suffer from Chronic Non-Healing Wounds
Diabetic Foot Ulcers Patients have a 30.5% 5-year mortality.
Dermatherix Milestones
-
Dermatherix is incorporated in Australia and is developing 3K3A-APC for the treatment of chronic wounds and skin diseases.
-
The wound healing technology was developed at the Royal North Shore Hospital in Sydney and The University of Sydney Kolling Medical Research Institute.
-
Chronic wound healing clinical studies demonstrated impressive results showing APC heals wounds that remained unclosed for multiple years, including difficult-to-treat diabetic foot ulcers
-
3K3A-APC has been shown to be superior to APC in wound healing studies.
-
Dermatherix has completed a pre-IND meeting with the FDA and is going into a Phase 2 clinical trial in Australia.
-
Further toxicity studies will precede commencement of a Phase 3 registrational trial.